Catalyst Event
Novo Nordisk A/S (NVO) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
3/20/2026, 12:00:00 AM
Patents for semaglutide, the active ingredient in Ozempic and Wegovy, expired in key markets including China and India. This event opens the door to generic competition in those regions.
Korean Translation
오젬픽과 위고비의 활성 성분인 세마글루타이드에 대한 특허가 중국 및 인도를 포함한 주요 시장에서 만료됨. 이로 인해 해당 지역에서 제네릭 경쟁이 가능해짐.
Related Recent Events
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast EPS around $7.25-$7.50 estimated. High importance estimated due to the significant weight of earnings reports on stock volatility.
4/30/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
Expected FDA decision date for oral obesity drug orforglipron scheduled. High importance estimated as FDA decisions for major drugs typically cause >10% price swings.
4/10/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Other
The ex-dividend date for the quarterly cash dividend of $1.25 per share is March 27, 2026, representing a 3% increase over the previous quarterly dividend.
3/27/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
Annual General Meeting 2026 scheduled.
3/26/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
HSBC downgraded the stock from 'Hold' to 'Reduce' with a price target of $850, citing valuation concerns and competitive pressures.
3/22/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
Announced positive topline results from the Phase 3 trial of retatrutide for type 2 diabetes, showing significant reductions in both blood sugar and weight.
3/19/2026, 12:00:00 AM